Skip to main content
Evolent Level 1 Medical Oncology

Pathways and Low-Value Regimens

Acute Lymphoblastic Leukemia (ALL), B-Cell

Regimen Options
Last Updated: 11/15/2024 See Details

NOTE: FOR RITUXIMAB, THE USE OF A BIOSIMILAR OR THE REFERENCE PRODUCT IS ON PATHWAY

Evolent Pathways Febrile Neutropenic Risk Emetogenic Risk References
INDUCTION & CONSOLIDATION & CNS PROPHYLAXIS (PER REGIMEN PROTOCOL)
 

Hyper-CVAD

High Moderate
 

Hyper-CVAD and rituximab

High Moderate
 

Hyper-CVAD and imatinib *if Ph positive*

High Moderate
 

CALGB 10403 (daunorubicin, vincristine, prednisone, pegaspargase)

High Moderate
 

CALGB 8811 (daunorubicin, vincristine, prednisone, pegaspargase, cyclophosphamide)

High Moderate
 

vincristine, dexamethasone

Low Low
 

vincristine, dexamethasone and imatinib *if Ph positive*

Low Low
 

blinatumomab and consolidation chemotherapy *MRD-negative remission*

High Low
MAINTENANCE
 

vincristine, methotrexate, 6-mercaptopurine

Low Low
 

vincristine, methotrexate, 6-mercaptopurine and imatinib *if Ph positive*

Low Low
 

vincristine, methotrexate, 6-mercaptopurine *if Ph negative*

Low Low
RELAPSED/REFRACTORY
 

blinatumomab

High Low
 

etoposide, ifosfamide and mitoxantrone

High Moderate
 

clofarabine

High Moderate
INDUCTION & CONSOLIDATION & CNS PROPHYLAXIS (PER REGIMEN PROTOCOL)
Evolent Pathways

Hyper-CVAD

Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
Evolent Pathways

Hyper-CVAD and rituximab

Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
Evolent Pathways

Hyper-CVAD and imatinib *if Ph positive*

Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
Evolent Pathways

CALGB 10403 (daunorubicin, vincristine, prednisone, pegaspargase)

Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
Evolent Pathways

CALGB 8811 (daunorubicin, vincristine, prednisone, pegaspargase, cyclophosphamide)

Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
Evolent Pathways

vincristine, dexamethasone

Febrile Neutropenic Risk
low
Emetogenic Risk
low
Evolent Pathways

vincristine, dexamethasone and imatinib *if Ph positive*

Febrile Neutropenic Risk
low
Emetogenic Risk
low
Evolent Pathways

blinatumomab and consolidation chemotherapy *MRD-negative remission*

Febrile Neutropenic Risk
high
Emetogenic Risk
low
MAINTENANCE
Evolent Pathways

vincristine, methotrexate, 6-mercaptopurine

Febrile Neutropenic Risk
low
Emetogenic Risk
low
Evolent Pathways

vincristine, methotrexate, 6-mercaptopurine and imatinib *if Ph positive*

Febrile Neutropenic Risk
low
Emetogenic Risk
low
Evolent Pathways

vincristine, methotrexate, 6-mercaptopurine *if Ph negative*

Febrile Neutropenic Risk
low
Emetogenic Risk
low
RELAPSED/REFRACTORY
Evolent Pathways

blinatumomab

Febrile Neutropenic Risk
high
Emetogenic Risk
low
Evolent Pathways

etoposide, ifosfamide and mitoxantrone

Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
Evolent Pathways

clofarabine

Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
Regimen Alternative References
LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES
 

venetoclax + chemotherapy (eg decitabine, hyper-CVAD, nelarabine, mini-hyper-CVD) *for T-cell*

Alternative: alkylator containing regimens: etoposide, ifosfamide, mitoxantrone

LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES
Regimen

venetoclax + chemotherapy (eg decitabine, hyper-CVAD, nelarabine, mini-hyper-CVD) *for T-cell*